Pimasertib (AS703026, MSC1936369B, AS-703026, MSC-1936369B)是可口服的、ATP非竞争性的MEK1/2变构抑制剂，具有抗癌活性。MEK/ERK通路在细胞存活、增殖和分化种有重要作用，在癌症中活性经常被上调。

参考文献

[1] Kim K, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Free Br J Haematol. 2010 May;149(4):537-49.

[2] Park SJ, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8.

[3] Yoon J, et al. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011 Jan 15;71(2):445-53.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。